Promising Star formations draw investors in $90M oversubscribed series C

Star Therapeutics Inc. brought on board six new investors in its oversubscribed $90 million series C round, raising the company’s total funding to more than $190 million since its founding in 2018 to advance in-house drug discovery efforts via formation of portfolio companies. Since emerging from stealth in early...

By |2023-09-15T15:42:40-04:00September 5, 2023|News Coverage|0 Comments

Stars align as ex-True North team nabs another $90M to build out biotech constellation

Star Therapeutics, which created two antibody-focused biotech startups with more in the works, has now reeled in a $90 million Series C. The round, disclosed Tuesday morning, brings the Bay Area biotech’s total financing to more than $190 million since emerging from Westlake Village BioPartners in early 2022. Star’s biotech startups Vega Therapeutics and Electra Therapeutics...

By |2023-09-15T15:44:01-04:00September 5, 2023|News Coverage|0 Comments

Investors shower Star Therapeutics with $90M for constellation of biotechs, antibody therapies

Investors have showered Star Therapeutics with $90 million to grow its portfolio companies and develop new antibody drugs for diseases with high unmet need. Sofinnova Investments led the oversubscribed series C round and was joined by new investors Qatar Investment Authority, Catalio Capital Management, Agent Capital, Soleus Capital and NYBC Ventures alongside all seven...

By |2023-09-15T15:44:45-04:00September 5, 2023|News Coverage|0 Comments

A new startup sets course against a constellation of rare diseases with a first shot repurposing the SIRP pathway

Despite some big advances in recent years, rare disease remains [...]

By |2022-12-05T18:39:02-05:00February 16, 2022|News Coverage|0 Comments

Star Therapeutics emerges with plans to treat rare diseases through a solar system of drug companies

The biotech has an unusual hub-and-spoke model that it believes [...]

By |2022-03-22T13:33:39-04:00February 16, 2022|News Coverage|0 Comments


We look forward to connecting with you